n-benzyladriamycin-14-valerate and ER-Negative PR-Negative HER2-Negative Breast Cancer

n-benzyladriamycin-14-valerate has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Gandhi, J; Lothstein, L; Parke, D; Seagroves, T; Soberman, J; Sweatman, T	1

Other Studies

1 other study(ies) available for n-benzyladriamycin-14-valerate and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo. Oncology research, 2020, Dec-10, Volume: 28, Issue:5 Topics: Animals; Anthracyclines; Antineoplastic Agents; Apoptosis; Cardiotoxicity; Cell Line, Tumor; Cell Survival; Doxorubicin; Female; Humans; Maximum Tolerated Dose; Mice; Mice, SCID; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays	2020

Article

Year

Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo.

Oncology research, 2020, Dec-10, Volume: 28, Issue:5

Topics: Animals; Anthracyclines; Antineoplastic Agents; Apoptosis; Cardiotoxicity; Cell Line, Tumor; Cell Survival; Doxorubicin; Female; Humans; Maximum Tolerated Dose; Mice; Mice, SCID; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2020